Eli Lilly in 2Q17: Performance of Neuroscience Products
Another franchise of Eli Lilly and Company’s (LLY) Human Pharmaceuticals segment is its neuroscience franchise. Key drugs in the franchise include Cymbalta, Strattera, and Zyprexa.
Interested in AGN? Don't miss the next report.
Receive e-mail alerts for new research on AGN
Cymbalta is an antidepressant used for the treatment of depression and anxiety and, at times, bone and muscle pain. Sales of Cymbalta fell ~13.0% to $206.6 million in 2Q17 compared to ~$236.5 million in 2Q16. US sales fell 22.0% to $47.1 million, and international sales fell 9.0% to $159.6 million in 2Q17.
Other drugs in the neuroscience franchise
Other drugs in the neuroscience franchise include Strattera and Zyprexa.
Strattera, a drug for attention deficit/hyperactivity disorder (or ADHD), reported a 17.0% fall in revenues to $186.6 million for 2Q17 compared to $224.6 million for 2Q16. US sales fell 29.0%, while international sales rose 5.0% in 2Q17.
Zyprexa is an antipsychotic drug used in the treatment of brain disorders such as schizophrenia and bipolar disorders. Sales for Zyprexa fell ~33.0% to $140.8 million in 2Q17 compared to $210.7 million for 2Q16. US sales fell 10.0% to $13.0 million, while international sales fell 35.0% to $127.8 million during 2Q17. Zyprexa, whose patent expired in Japan in June 2016, reported a ~56.0% fall in revenues for 2Q17 due to lower sales following generic competition.
To divest the company-specific risks, you can consider the Health Care Select Sector SPDR ETF (XLV), which holds 2.7% of its total assets in Eli Lilly. XLV also holds 11.5% in Johnson & Johnson (JNJ), 6.3% in Merck & Co. (MRK), and 3.2% in Allergan (AGN).